189 related articles for article (PubMed ID: 1531693)
1. Cholesterol alters the binding of Ca2+ channel blockers to the membrane lipid bilayer.
Mason RP; Moisey DM; Shajenko L
Mol Pharmacol; 1992 Feb; 41(2):315-21. PubMed ID: 1531693
[TBL] [Abstract][Full Text] [Related]
2. Comparison of location and binding for the positively charged 1,4-dihydropyridine calcium channel antagonist amlodipine with uncharged drugs of this class in cardiac membranes.
Mason RP; Campbell SF; Wang SD; Herbette LG
Mol Pharmacol; 1989 Oct; 36(4):634-40. PubMed ID: 2554114
[TBL] [Abstract][Full Text] [Related]
3. Conserved Ca2+-antagonist-binding properties and putative folding structure of a recombinant high-affinity dihydropyridine-binding domain.
Huber I; Wappl E; Herzog A; Mitterdorfer J; Glossmann H; Langer T; Striessnig J
Biochem J; 2000 May; 347 Pt 3(Pt 3):829-36. PubMed ID: 10769189
[TBL] [Abstract][Full Text] [Related]
4. Lercanidipine: short plasma half-life, long duration of action and high cholesterol tolerance. Updated molecular model to rationalize its pharmacokinetic properties.
Herbette LG; Vecchiarelli M; Sartani A; Leonardi A
Blood Press Suppl; 1998; 2():10-7. PubMed ID: 9850437
[TBL] [Abstract][Full Text] [Related]
5. Quantification of the calcium antagonism of lacidipine by kinetic analysis.
Giacometti A; Micheli D; Gaviraghi G; Trist DG
J Pharmacol Exp Ther; 1994 Apr; 269(1):424-9. PubMed ID: 8169848
[TBL] [Abstract][Full Text] [Related]
6. The unique binding properties of amlodipine: a long-acting calcium antagonist.
Nayler WG; Gu XH
J Hum Hypertens; 1991 Aug; 5 Suppl 1():55-9. PubMed ID: 1834847
[TBL] [Abstract][Full Text] [Related]
7. Residual inhibition in density of [3H]isradipine binding sites in rat brain membrane pretreated with amlodipine.
Qu YL; Takamizawa C; Sugiyama K; Maruyama K; Hattori K; Watanabe K; Nagatomo T
Zhongguo Yao Li Xue Bao; 1995 Jul; 16(4):289-93. PubMed ID: 7668092
[TBL] [Abstract][Full Text] [Related]
8. Effect of inorganic calcium channel blockers on dihydropyridine binding to cardiac sarcolemma.
Schilling WP; Zaher MC; Rampe D
Mol Pharmacol; 1990 Jan; 37(1):80-9. PubMed ID: 2137194
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological in vitro studies of the new 1,4-dihydropyridine calcium antagonist lercanidipine.
Guarneri L; Angelico P; Ibba M; Poggesi E; Taddei C; Leonardi A; Testa R
Arzneimittelforschung; 1996 Jan; 46(1):15-24. PubMed ID: 8821512
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of calcium channel inhibition by phenytoin: comparison with classical calcium channel antagonists.
Messing RO; Carpenter CL; Greenberg DA
J Pharmacol Exp Ther; 1985 Nov; 235(2):407-11. PubMed ID: 2414431
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of cancer cell growth by calcium channel antagonists in the athymic mouse.
Taylor JM; Simpson RU
Cancer Res; 1992 May; 52(9):2413-8. PubMed ID: 1533173
[TBL] [Abstract][Full Text] [Related]
12. Interaction of charged and uncharged calcium channel antagonists with phospholipid membranes. Binding equilibrium, binding enthalpy, and membrane location.
Bäuerle HD; Seelig J
Biochemistry; 1991 Jul; 30(29):7203-11. PubMed ID: 1830218
[TBL] [Abstract][Full Text] [Related]
13. Vascular and myocardial effects of amlodipine: an overview.
Nayler WG; Gu XH
Postgrad Med J; 1991; 67 Suppl 5():S41-3. PubMed ID: 1839439
[TBL] [Abstract][Full Text] [Related]
14. SR 33557, a novel calcium entry blocker. II. Interactions with 1,4-dihydropyridine, phenylalkylamine and benzothiazepine binding sites in rat heart sarcolemmal membranes.
Nokin P; Clinet M; Beaufort P; Meysmans L; Laruel R; Chatelain P
J Pharmacol Exp Ther; 1990 Nov; 255(2):600-7. PubMed ID: 2147036
[TBL] [Abstract][Full Text] [Related]
15. Molecular basis for the inhibition of 1,4-dihydropyridine calcium channel drugs binding to their receptors by a nonspecific site interaction mechanism.
Young HS; Skita V; Mason RP; Herbette LG
Biophys J; 1992 May; 61(5):1244-55. PubMed ID: 1318093
[TBL] [Abstract][Full Text] [Related]
16. Subunit composition is a major determinant in high affinity binding of a Ca2+ channel blocker.
Suh-Kim H; Wei X; Birnbaumer L
Mol Pharmacol; 1996 Nov; 50(5):1330-7. PubMed ID: 8913365
[TBL] [Abstract][Full Text] [Related]
17. High-affinity antibodies to the 1,4-dihydropyridine Ca2+-channel blockers.
Campbell KP; Sharp A; Strom M; Kahl SD
Proc Natl Acad Sci U S A; 1986 May; 83(9):2792-6. PubMed ID: 3010317
[TBL] [Abstract][Full Text] [Related]
18. High-affinity binding of DTZ323, a novel derivative of diltiazem, to rabbit skeletal muscle L-type Ca++ channels.
Hagiwara M; Adachi-Akahane S; Nagao T
J Pharmacol Exp Ther; 1997 Apr; 281(1):173-9. PubMed ID: 9103495
[TBL] [Abstract][Full Text] [Related]
19. Kinetics of binding of membrane-active drugs to receptor sites. Diffusion-limited rates for a membrane bilayer approach of 1,4-dihydropyridine calcium channel antagonists to their active site.
Rhodes DG; Sarmiento JG; Herbette LG
Mol Pharmacol; 1985 Jun; 27(6):612-23. PubMed ID: 2987659
[TBL] [Abstract][Full Text] [Related]
20. The pharmacological profile of amlodipine in relation to ischaemic heart disease.
Burges RA
Postgrad Med J; 1991; 67 Suppl 3():S9-15. PubMed ID: 1836872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
